Search

Displaying results 2571 - 2580 of 10000 in total
  1. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039] It is a RAS(ON) tri-complex inhibitor that binds cyclophilin A and targets the active, GTP-bound ("ON") state of RAS, suppressing signaling of both wild-type and mutant RAS across the most common … Daraxonrasib is an orally administered, multi-selective inhibitor of the RAS GTPase family used to treat metastatic pancreatic adenocarcinoma.

  2. Drug

    Bromocriptine

    go.drugbank.com/drugs/DB01200
    ApprovedInvestigationalWithdrawn

    In 1995, the FDA withdrew the approval of bromocriptine mesylate for the prevention of physiological lactation after finding that bromocriptine was not shown to be safe for use. … Bromocriptine has been associated with pulmonary fibrosis, and can also cause sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly.

  3. Drug

    Dimethyl sulfoxide

    go.drugbank.com/drugs/DB01093
    ApprovedInvestigationalVet approved

    A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue dur...

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.

  5. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    in Pompe disease. … ,[L45275] and the EMA fully approved the drug on March 27, 2023.

  6. Drug

    Hyaluronidase

    go.drugbank.com/drugs/DB14740
    ApprovedInvestigational

    [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … [L13338] The action of hyaluronidase was first described in 1936, and named in 1939.

  7. Drug

    Curcumin

    go.drugbank.com/drugs/DB11672
    ApprovedInvestigational

    Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in [Curcuma xanthorrhiza oil].

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Tea tree oil

    go.drugbank.com/drugs/DB11218
    ApprovedNutraceutical

    Tea tree oil is an essential oil derived mainly from the Australian native plant _Melaleuca alternifolia_ via steam distillation of the of the leaves and terminal branches [A32439]. … It has been a popular ingredient in a variety of household and cosmetic products due to its antiseptic, anti-inflammatory, broad-spectrum antimicrobial and antioxidant properties [A32438].

    Synonyms: Snow-in-summer leaf oil
  9. Drug

    Flucytosine

    go.drugbank.com/drugs/DB01099
    ApprovedInvestigational

    A fluorinated cytosine analog that is used as an antifungal agent.

  10. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    with an HCV regimen containing sofosbuvir without an NS5A inhibitor [L935]. … Notably, Vosevi is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection and have previously been treated